BRSL enters the post-earnings period under real pressure. A Q1 miss, a fresh 12-month low, and a month-long build in short interest have converged in a single ugly week.
The catalyst was Tuesday's earnings release. Brightstar Lottery missed EPS estimates by $0.04, and the market's reaction was swift — the stock fell 9.6% on the day to $11.55, a new 52-week low. The decline brings the one-month loss to 5.7% and erases progress that bulls had been pointing to. The bear case is now visible: the UK business continues to drag, revenue amortization from upfront fees is eating into the headline numbers, and FX remains a live risk given the company's material euro exposure.
Short sellers have been building positions for most of the past month. Short Interest as a % of Free Float climbed from 4.3% in mid-April to just under 6% by May 12 — a 24% increase over 30 days and the highest reading in the data window. The one-week jump alone is over 10%. That said, the borrow market itself remains loose. Cost to borrow is just 0.50%, barely changed from where it was a month ago. Availability has not tightened meaningfully. The short score of 44.1 — up from 40.3 ten days ago — reflects a building but not extreme bearish positioning. This looks more like a measured re-rating by fundamental short sellers than a crowded momentum pile-on.
Options sentiment is in line with that read. The put/call ratio of 0.68 is virtually identical to its 20-day average of 0.68, with a z-score near zero. The 52-week high on PCR is 0.87, and the current reading is well below that ceiling. Options traders are not scrambling for downside protection in the way they did in mid-April, when the PCR briefly spiked above 0.81. The positioning is cautious but not panicked.
The Street reacted quickly to the print. Truist, maintaining its Hold, cut its price target from $17 to $14 — putting it level with where Jefferies already landed after their April trim. Stifel, the most persistent bull in the name, held its Buy but trimmed from $20 to $19. Those moves are meaningful: the mean price target is now $17.08 against a stock trading at $11.55, implying nearly 48% upside on paper. That gap is large, but it reflects the distance between a bull case built on medium-term EBITDA recovery and a stock that keeps finding new lows. The company's own maintained guidance of $2.5B in revenue and $1.1B adjusted EBITDA for 2025 is the anchor for bulls; the bear case is that headline guidance hasn't moved even as conditions worsen.
Valuation is worth noting in isolation. At 4.8x EV/EBITDA and a P/B of just over 1x, BRSL is not priced for growth. The EV/EBITDA multiple has compressed 20 basis points over the past week as the stock fell and the company's enterprise value declined. The EV/EBIT factor rank of 84 suggests the stock screens as cheap on earnings-power metrics relative to the broader universe — a data point the bull case leans on heavily.
With no next earnings event currently confirmed, the near-term focus shifts to whether short interest continues its steady grind higher or whether the valuation floor starts attracting buyers at these levels.
See the live data behind this article on ORTEX.
Open BRSL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
